Zobrazeno 1 - 10
of 1 397
pro vyhledávání: ''
Autor:
Hong Luo, Yi Hu, Patricia Keegan, Hongqian Guo, Ji-Yan Liu, Haige Chen, Sheng Yao, Weifeng Wang, Jun Guo, Fangjian Zhou, Xudong Yao, Benkang Shi, Zhigang Ji, Hui Feng, Xinan Sheng, Zhisong He, Bin Hu, Ziling Liu, Jin Wu, Xin Yao, Jinhai Fan, Yiran Huang
Publikováno v:
Clinical Cancer Research. 28:489-497
Purpose: Immunotherapy offers a second-line option for patients with metastatic urothelial carcinoma (mUC) who failed standard therapy, but the biomarkers for predicting response remain to be explored. This study aims to evaluate the safety, efficacy
Autor:
Chana Weinstock, Laleh Amiri-Kordestani, Xiao Hong Chen, Elaine Chang, Eias Zahalka, Jeanne Fourie Zirkelbach, Shenghui Tang, Amna Ibrahim, Mallorie H. Fiero, Julia A. Beaver, Kirsten B. Goldberg, Vishal Bhatnagar, Miao Zhao, Paul G. Kluetz, Richard Pazdur, Tiffany K. Ricks, Jingyu Yu, Junshan Qiu, Lijun Zhang
Publikováno v:
Clin Cancer Res
On March 10, 2021, the FDA granted regular approval to tivozanib for treatment of patients with relapsed or refractory (R/R) advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. Approval was based on the TIVO-3 study, a
Autor:
Joanne Xiu, Michael J. Pishvaian, Ari M. Vanderwalde, Jia Zeng, Yasmine Baca, Sunnie S. Kim, John L. Marshall, W. Michael Korn, Anthony F. Shields, Axel Grothey, Heinz-Josef Lenz, Philip A. Philip, Mohamed E. Salem, Jimmy J. Hwang, Richard M. Goldberg, Michael Cerniglia
Publikováno v:
Mol Cancer Ther
The prevalence of homologous recombination–DNA damage response (HR-DDR) genetic alterations is of therapeutic interest in gastroesophageal cancers. This study is a comprehensive assessment of HR-DDR mutation prevalence across gastroesophageal adeno
Autor:
Qinghua Han, Lindsey A. Barner, Lawrence D. True, Chenyi Mao, Andrew Janowczyk, Pingfu Fu, Robert Serafin, Nicholas P. Reder, Anant Madabhushi, Jonathan T. C. Liu, Can Fahrettin Koyuncu, Patrick Leo, Sarah Hawley, Weisi Xie, Hongyi Huang, Jonathan L. Wright, Gan Gao, Adam K. Glaser, Soyoung Kang, Kevin Bishop, Nadia Postupna, C. Dirk Keene, Joshua C. Vaughan
Publikováno v:
Cancer Res
Prostate cancer treatment planning is largely dependent upon examination of core-needle biopsies. The microscopic architecture of the prostate glands forms the basis for prognostic grading by pathologists. Interpretation of these convoluted three-dim
Autor:
Eva Karamitopoulou, Aurélie Pahud de Mortanges, Aurel Perren, Beat Gloor, Andreas Andreou, Marianne Tinguely
Publikováno v:
Cancer Immunology Research. 9:1439-1450
Immunotherapy, including PD-1/PD-L1 agonists, has shown limited efficacy in pancreatic ductal adenocarcinoma (PDAC). We examined the PD-1/PD-L1 expression and immunoarchitectural features by automated morphometric analysis using multiplex immunofluor
Autor:
Kimia Sobhani, Jennifer E. Van Eyk, James L. Stewart, Warren G. Tourtellotte, Justin Darrah, Joslyn Foley, Wendy Cozen, Karen L. Reckamp, Susan Cheng, Alain C. Mita, So Yung Choi, Carissa A. Huynh, Noah Merin, Sandy Joung, Tucker Lemos, Robert Vescio, Ronald Paquette, Dermot P.B. McGovern, Edwin C. Frias, John Prostko, Omid Hamid, Joseph E. Ebinger, Emebet Mengesha, Reva Basho, Greg Botwin, Jun Gong, Nathalie Nguyen, Jonathan Braun, Inderjit Mehmi, Jane C. Figueiredo, Akil Merchant, Gil Y. Melmed, Laurel J Finster
Publikováno v:
Cancer Res
Longitudinal studies of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine-induced immune responses in patients with cancer are needed to optimize clinical care. In a prospective cohort study of 366 (291 vaccinated) patients, we mea
Autor:
Lene Hjerrild Iversen, Claus L. Andersen, Derrick Renner, Thomas Reinert, Ole Thorlacius-Ussing, Desamparados Roda, Tenna V Henriksen, Alexey Aleshin, Andrés Cervantes, Noelia Tarazona, Per Vadgaard Andersen, Shruti Sharma, Susana Roselló, J.A. Carbonell-Asins, Dina Hafez, Anders Husted Madsen, Uffe S. Løve, Kåre Andersson Gotschalck, Amanda Frydendahl, Marisol Huerta, F. Gimeno-Valiente, Himanshu Sethi
Publikováno v:
Henriksen, T V, Tarazona, N, Frydendahl, A, Reinert, T, Gimeno-Valiente, F, Carbonell-Asins, J A, Sharma, S, Renner, D, Hafez, D, Roda, D, Huerta, M, Roselló, S, Madsen, A H, Løve, U S, Andersen, P V, Thorlacius-Ussing, O, Iversen, L H, Gotschalck, K A, Sethi, H, Aleshin, A, Cervantes, A & Andersen, C L 2022, ' Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences ', Clinical Cancer Research, vol. 28, no. 3, pp. 507-517 . https://doi.org/10.1158/1078-0432.CCR-21-2404
Clinical cancer research : an official journal of the American Association for Cancer Research
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Clinical cancer research : an official journal of the American Association for Cancer Research
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Purpose: Sensitive methods for risk stratification, monitoring therapeutic efficacy, and early relapse detection may have a major impact on treatment decisions and patient management for stage III colorectal cancer patients. Beyond assessing the pred
Autor:
John H. Strickler, Johanna C. Bendell, Samuel J. Klempner, James B. Rottman, Michael H. Kagey, Stacey Stein, Girish S. Naik, Marya F. Chaney, Victoria M. Villaflor, Laura LaNiel Tenner, Cynthia A. Sirard
Publikováno v:
Molecular Cancer Therapeutics. 20:2240-2249
Therapeutic combinations targeting innate and adaptive immunity and predictive biomarkers of response in esophagogastric cancer (EGC) are needed. We assessed safety and clinical utility of DKN-01 (a novel DKK1-neutralizing IgG4 antibody) combined wit
Autor:
Graham McLennan, Amin Mazloom, Gregory A. Daniels, Daniel S. Grosu, Marcia Eisenberg, Razelle Kurzrock, Kimberly A. Holden, Shumei Kato, Prachi Nakashe, Kerry D. Fitzgerald, Eyad Almasri, Taylor J. Jensen, Christopher K. Ellison, Erin McCarthy, Lisa Kim, Aaron M. Goodman
Publikováno v:
Molecular Cancer Therapeutics. 20:2274-2279
When tissue biopsy is not medically prudent or tissue is insufficient for molecular testing, alternative methods are needed. Because cell-free DNA (cfDNA) has been shown to provide a representative surrogate for tumor tissue, we sought to evaluate it
Autor:
Alvin M. Matsumoto, Nima Sharifi, Michael T. Schweizer, Heather H. Cheng, R. Bruce Montgomery, Mary-Ellen Taplin, P.W. Kantoff, Felix S. Chew, Evan Y. Yu, Orpheus Kolokythas, Steven P. Balk, Peter S. Nelson, Brett T. Marck, Elahe A. Mostaghel
Publikováno v:
Clin Cancer Res
Purpose: In metastatic castration-resistant prostate cancer (mCRPC) low serum androgens prior to starting abiraterone acetate (AA) is associated with more rapid progression. We evaluated the effect of AA on androgens in castration-resistant prostate